Patrícia Amorós-Reboredo1, Jaime Sánchez-López2, Carla Bastida-Fernández3, Fernando do Pazo-Oubiña4, Núria Borràs-Maixenchs5, Eva Giné6, Antonio Valero7, Natàlia Creus-Baró3. 1. Pharmacy Department, Hospital Clinic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. pamoros1@clinic.ub.es. 2. Allergy Unit, Pneumology and Respiratory Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic (ICT), University of Barcelona, Barcelona, Spain. 3. Pharmacy Department, Hospital Clinic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. 4. Pharmacy Department, Hospital Son Espases, Palma de Mallorca, Spain. 5. Haematology Department, Hospital Clínic, Barcelona, Spain. 6. Haematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain. 7. Allergy Unit, Pneumology and Respiratory Department, Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic (ICT), University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols. OBJECTIVE: To present our experience working as a multidisciplinary team using a rituximab rapid desensitization scheme. METHOD: Patient demographics, allergic reaction, skin tests to rituximab, number of desensitizations, reactions during the desensitization protocol and actions taken, number of administered and completed cycles, were retrospectively collected in patients who received at least one desensitization to rituximab. MAIN OUTCOMES: Number of desensitizations successfully managed. RESULTS: Between 2012 and June 2013 five patients received a total of 19 desensitizations to rituximab using a 12 step rapid desensitization protocol. All patients received the scheduled chemotherapeutic cycles as inpatients, with no delay in administration dates. Three patients presented a hypersensitivity reaction during the first desensitization and in one patient the event occurred again during the second treatment cycle. All reactions occurred in the last step, when the infusion rate reached the maximum speed. CONCLUSION: The developed protocol for rapid desensitization was successful in five patients receiving rituximab. Patients could receive the full intended dose.
BACKGROUND: The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols. OBJECTIVE: To present our experience working as a multidisciplinary team using a rituximab rapid desensitization scheme. METHOD:Patient demographics, allergic reaction, skin tests to rituximab, number of desensitizations, reactions during the desensitization protocol and actions taken, number of administered and completed cycles, were retrospectively collected in patients who received at least one desensitization to rituximab. MAIN OUTCOMES: Number of desensitizations successfully managed. RESULTS: Between 2012 and June 2013 five patients received a total of 19 desensitizations to rituximab using a 12 step rapid desensitization protocol. All patients received the scheduled chemotherapeutic cycles as inpatients, with no delay in administration dates. Three patients presented a hypersensitivity reaction during the first desensitization and in one patient the event occurred again during the second treatment cycle. All reactions occurred in the last step, when the infusion rate reached the maximum speed. CONCLUSION: The developed protocol for rapid desensitization was successful in five patients receiving rituximab. Patients could receive the full intended dose.
Entities:
Keywords:
Desensitization; Drug hypersensitivity; Rituximab; Spain
Authors: Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis Journal: J Allergy Clin Immunol Date: 2008-05-27 Impact factor: 10.793
Authors: Patrick J Brennan; Tito Rodriguez Bouza; F Ida Hsu; David E Sloane; Mariana C Castells Journal: J Allergy Clin Immunol Date: 2009-12 Impact factor: 10.793
Authors: R Madrigal-Burgaleta; M P Berges-Gimeno; D Angel-Pereira; R Ferreiro-Monteagudo; C Guillen-Ponce; C Pueyo; E Gomez de Salazar; E Alvarez-Cuesta Journal: Allergy Date: 2013-05-06 Impact factor: 13.146